Perpetuals.com Ltd (NASDAQ: PDC) announced it is applying its BayesShield AI technology, originally developed for financial trading predictions, to healthcare diagnostic accuracy. The company stated the system aims to identify which physicians demonstrate the most accurate diagnostic patterns for specific case types.

The technology does not diagnose patients or replace physician judgment, according to the company. Instead, it analyzes statistical patterns to help hospitals optimize case routing, second-opinion protocols, and training programs.

"We built BayesShield to find why traders lose money, hidden under layers of behavioral noise. The same methodology works in other high-stakes decisions, including healthcare," said Patrick Gruhn, CEO of Perpetuals.

The company cited research indicating that 795,000 patients in the United States die or are permanently disabled annually due to diagnostic errors, based on a 2024 Johns Hopkins study published in BMJ Quality & Safety. Additional studies referenced show cognitive biases are associated with diagnostic inaccuracies in up to 77% of case scenarios.

Perpetuals has partnered with the European Institute of Management (EIM) for clinical implementation. Under the arrangement, Perpetuals provides the software platform while EIM manages pilot deployment and trial design with partner hospitals. EIM's PhD in Healthcare Studies program will provide academic oversight for the clinical pilots.

The BayesShield platform was trained on over 11.7 billion retail trades from derivatives trading venues. The company operates a licensed European Multilateral Trading Facility and the Kronos X trading platform.

Information is based on a company press release.